(Hypertension. 1997;29:815-821.)
© 1997 American Heart Association, Inc.
Articles |
the Departments of Medicine (Endocrine-Hypertension Division) and Radiology, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass.
Correspondence to Dr Steven W. Graves, Endocrine-Hypertension Division, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115. E-mail swgraves@bics.bwh.harvard.edu
We have isolated a labile, specific sodium pump inhibitor or digitalis-like factor from the peritoneal dialysate of volume-expanded renal failure patients whose levels correlated closely with volume status and blood pressure. This study characterizes the inhibitory profile of this agent compared with that of ouabain against the three
-isoforms of the sodium pump. We prepared microsomal Na,K-ATPase from rat tissues representing the highest proportion of one of the
-isoforms. Both Northern and Western blot analyses confirmed that kidney had predominantly the
1-isoform, skeletal muscle the
2-isoform, and fetal brain the
3-isoform. Ouabain (5x10-6 mol/L) produced little inhibition of kidney Na,K-ATPase (3.4±2.0%) but significant inhibition of skeletal muscle (37.2±3.7%, P<.001) and fetal brain (38.8±3.5%, P<.001) activity. In contrast, the labile digitalis-like factor, causing comparable inhibition of fetal brain Na,K-ATPase activity (33.3±4.7%), produced markedly greater inhibition of kidney (42.5±5.6%, P<.001) and moderately greater inhibition of skeletal muscle pump activity (57.7±6.3%, P<.05). In addition, the labile digitalis-like factor produced a marked concentration-dependent inhibition of the
2- and
3-isoforms (r=.79, P=.00005). Experiments combining the labile digitalis-like factor and ouabain confirmed that digitalis-like factor, unlike ouabain, was an effective inhibitor of all three isoforms in rat, in particular
2. The different pattern of isoform sensitivity displayed by the labile digitalis-like factor and ouabain further differentiates the two agents and raises some interesting possibilities about the functional implications of the endogenous factor.
Key Words: mRNA Western blot analysis ouabain Na+,K+-transporting ATPase sodium pump digitalis-like factor
This article has been cited by other articles:
![]() |
J. A. Wasserstrom and G. L. Aistrup Digitalis: new actions for an old drug Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1781 - H1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M.A.M. Qazzaz, Z. Cao, D. D. Bolanowski, B. J. Clark, and R. Valdes Jr De Novo Biosynthesis and Radiolabeling of Mammalian Digitalis-Like Factors Clin. Chem., March 1, 2004; 50(3): 612 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shimoda, J. Jasleen, J. D. Rounds, S. W. Ashley, and D. O. Jacobs Sepsis Increases the Plasma Membrane Content of {alpha}1 and {alpha}2 Isoforms of Na+-K+ Adenosine Triphosphatase in Rat Skeletal Muscle Arch Surg, January 1, 2001; 136(1): 95 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Graves, K. E. Markides, and N. K. Hollenberg Application of Supercritical Fluid Chromatography to Characterize a Labile Digitalis-Like Factor Hypertension, December 1, 2000; 36(6): 1059 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. A. M. Qazzaz, M. A. El-Masri, and R. Valdes Jr. Secretion of a Lactone-Hydrogenated Ouabain-Like Effector of Sodium, Potassium-Adenosine Triphosphatase Activity by Adrenal Cells Endocrinology, September 1, 2000; 141(9): 3200 - 3209. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-F. Tao, N. K. Hollenberg, and S. W. Graves Sodium Pump Inhibition and Regional Expression of Sodium Pump {alpha}-Isoforms in Lens Hypertension, November 1, 1999; 34(5): 1168 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Orlov, N. C. Adragna, V. A. Adarichev, and P. Hamet Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension Am J Physiol Cell Physiol, March 1, 1999; 276(3): C511 - C536. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Bagrov, O. V. Fedorova, R. I. Dmitrieva, W. N. Howald, A. P. Hunter, E. A. Kuznetsova, and V. M. Shpen Characterization of a Urinary Bufodienolide Na+,K+-ATPase Inhibitor in Patients After Acute Myocardial Infarction Hypertension, May 1, 1998; 31(5): 1097 - 1103. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |